David M. Epstein, Ph.D.

David M. Epstein, Ph.D.

DirectoratBlack Diamond Therapeutics· In proxies 2022–2025

Pay in FY2023+23% from the year before · Black Diamond Therapeutics stock +56.1% the same year

David M. Epstein, Ph.D. was paid $2.0M in FY2023 (Dec), up 23%. Black Diamond Therapeutics stock rose 56.1% that year.

Pay$100 in the stock at the end of FY21 → $53
Pay is from the Summary Compensation Table of each Black Diamond Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Gyre TherapeuticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Black Diamond TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role -65%
  3. MetaStat, Inc.Public company · 2 yr
    • Director2013 – 2015 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?